Dr. Eduardo Candelario-Jalil is a tenured Associate Professor in the Department of Neuroscience, McKnight Brain Institute, University of Florida. Dr. Candelario-Jalil’s research interests have been fostered by nineteen years of work in neuropharmacology, biochemistry and molecular biology. Dr. Candelario-Jalil’s postdoctoral training in Germany and the United States focused upon elucidating the mechanisms underlying the neuroprotective ability of cyclooxygenase-2 (COX-2) inhibitors in experimental animal models of ischemic injury (focal ischemic stroke induced by middle cerebral artery occlusion and global forebrain ischemia). His current research activities are focused on identifying novel molecular targets to reduce blood-brain barrier (BBB) damage following ischemic stroke. His laboratory is currently investigating the neurovascular effects of adropin, a recently-identified peptide, in animal models of ischemic stroke. Another main area of research involves the study of the role of bromodomain and extraterminal domain (BET) proteins in the neuroinflammatory response to ischemic stroke.
Dr. Candelario-Jalil directs an active research program with great translational potential, which is currently funded by two R01 grants from the NIH. Research is focused on understanding neuroinflammatory mechanisms following ischemic stroke utilizing biochemical, cellular, genetic, pharmacological, and MRI multimodal approaches. As encouraged by the NIH/NINDS Roadmap, this type of translational research is of fundamental importance in accelerating the development of effective stroke therapeutics.
Dr. Candelario-Jalil have authored 69 original peer-reviewed publications, 11 invited review articles, and 3 book chapters. He has made significant contributions to the understanding of neuroinflammatory mechanisms in ischemic stroke as demonstrated by several research articles published in high-profile and prestigious journals in the field such as Stroke, Journal of Neurochemistry, Journal of Neuroscience, Journal of Cerebral Blood Flow and Metabolism, Journal of Pharmacology & Experimental Therapeutics, and Journal of Neuroinflammation. Dr. Candelario-Jalil’s work has been extensively cited (3,602 citations for all publications as of January 2021) with an h-index of 35.
- Advanced MRI and stroke
- Blood biomarkers and stroke
- Neuroimmune interactions in Neurodegenerative diseases
- Protective and preventive measures of cerebrovascular disorders (cerebral ischemia, vascular remodeling and neurological imaging)
- Stroke recovery
- cerebral ischemia